Iotroxic acid

Structural formula
General
Non-proprietary name	Iotroxic acid
other names	3,3 '- (1,11-Dioxo-3,6,9-trioxaundecamethylenediamino) bis (2,4,6-triiodobenzoic acid) ( IUPAC )
Molecular formula	C 22 H 18 I 6 N 2 O 9 ; C 36 H 52 I 6 N 4 O 19 (iotroxate dimeglumine) ;
External identifiers / databases
EC number	256-917-3
ECHA InfoCard	100.051.726
PubChem	3740
Wikidata	Q3183847
Drug information
ATC code	V08 AC02
properties
Molar mass	1215.81 g · mol -1 ; 1606.24 g · mol -1 (Iotroxat dimeglumine) ;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Iotroxic acid is an iodine-containing contrast medium that is used in radiology to visualize the gallbladder and ducts. Is used medicinally the water-soluble Di meglumine salt ( Iotroxat dimeglumine ) used as infusion over 20 to 60 minutes intravenously administered.

Iotroxic acid is actively secreted by the liver cells and, because of its high hepatocellular transport rate, leads to a high degree of contrast density in the intra- and extrahepatic bile ducts and in the gallbladder. There is hardly any excretion via the kidneys and only occurs when the maximum transport capacity of the liver cells is exceeded.

Like amidotrizoic acid, iotroxic acid is structurally derived from triiodobenzoic acid . In 1985 iotroxic acid was added to the list of essential medicines of the World Health Organization .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Technical information Biliscopin infusion solution (Bayer Austria), as of December 2001.
^ The WHO Essential Medicines Library, meglumine iotroxate .

Trade names

Biliscopin (in D, A and CH except for trade)

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] Technical information Biliscopin infusion solution (Bayer Austria), as of December 2001.

[3] The WHO Essential Medicines Library, meglumine iotroxate .